Cell Death Discovery · 2024 · 15 citations · 37 references
Life SciencesCancer BiologyMolecular BiologyChromatin BiologyEpigeneticsMolecular OncologyCancer EpigeneticsCancer GenomicsCancer TranscriptomicsChromatinEpigenetic Alterations In CancerEpigenetic Regulation In CancerAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyAssay For Transposase-accessible Chromatin Using SequencingChromosome RearrangementsCytogenetic AbnormalitiesEpigenetic TherapiesHistone AcetylationWestern Blot Analysis
Acute myeloid leukemia (AML) with mixed-lineage leukemia (MLL) gene rearrangements (MLL-r) is an aggressive subtype of blood cancer with dismal prognosis, underscoring the urgent need for novel therapeutic strategies. E1A-binding protein (EP300) and CREB-binding protein (CREBBP) function as essential transcriptional coactivators and acetyltransferases, governing leukemogenesis through diverse mechanisms. Targeting EP300/CREBBP holds great promise for treating leukemia with some certain cytogenetic abnormalities. Here, we demonstrated that EP300 and CREBBP are core epigenetic regulators in the pathogenesis of MLL-r AML through assaying the transposase-accessible chromatin with high-throughput sequencing (ATAC-seq). Knocking-out EP300/CREBBP and inhibitor (A-485) treatment depressed the MLL-r cells proliferation, while the MLL wild-type cells remained uninfluenced. We found that the CDK4/RB/E2F axis was downregulated specifically in MLL-r AML cell after A-485 treatment by RNA-seq, western blot and cut-tag analyses. EP300/CREBBP inhibitor selectively exerted potent anti-leukemia activity through blocking the MLL-r-BET complex binding to H3K27Ac modification on critical genes loci, distinct from global histone acetylation. Collectively, our study identified EP300/CREBBP as a critical epigenetic driver of MLL-r leukemia and validated their therapeutic potential through targeting inhibition, offering a promising avenue for improving clinical outcomes in this aggressive leukemia.
37
Damian Szklarczyk, Katerina Nastou, David Lyon et al. · Nucleic Acids Research · 2020 · 8.6K citations · Full text
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Andrei V. Krivtsov, David Twomey, Zhaohui Feng et al. · Nature · 2006 · 1.5K citations
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text
The chromatin accessibility landscape of primary human cancers
M. Ryan Corces, Jeffrey M. Granja, Shadi Shams et al. · Science · 2018 · 1.3K citations · Full text